Study of new drugs for HR+/HER2- advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer must be HR+ and HER2-, meaning it grows in response to hormones but not to a protein called HER2.
- Your cancer cannot be removed with surgery and has spread to other parts of the body (advanced or metastatic).
- You must have tried at least one hormone therapy that included a CDK4/6 inhibitor, and your cancer kept getting worse.
- You must be well enough to possibly receive chemotherapy (ECOG score 0-1).
- You cannot have had prior chemotherapy for advanced or metastatic breast cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with early-stage, high-risk breast cancer that hasn't spread. The drug is given before surgery to see if it can shrink tumors and improve outcomes.
This trial tests a combination of two drugs, sacituzumab tirumotecan and pembrolizumab, given before surgery for triple-negative breast cancer (a type of breast cancer that lacks three common markers). The study aims to see if this treatment can shrink tumors and improve outcomes.
This trial tests a combination of two drugs (sacituzumab tirumotecan and pembrolizumab) as a first maintenance treatment for cervical cancer that has spread or come back. It is for people who haven't had other cancer treatments for this stage and whose tumors have a certain protein marker (PD-L1).
This trial tests a new targeted drug (sacituzumab tirumotecan) for people with advanced thymic cancer that has gotten worse after at least one prior treatment. The goal is to see if the drug can shrink tumors and improve outcomes.
This trial tests a new investigational drug (MK-2010) combined with sacituzumab tirumotecan (Sac-TMT) for people with various solid tumors. The goal is to see if the combination is safe and effective.
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.